BR0210645A - Composto derivado de tetraidroquinolina, composição farmacêutica, e, uso do composto. - Google Patents

Composto derivado de tetraidroquinolina, composição farmacêutica, e, uso do composto.

Info

Publication number
BR0210645A
BR0210645A BR0210645-0A BR0210645A BR0210645A BR 0210645 A BR0210645 A BR 0210645A BR 0210645 A BR0210645 A BR 0210645A BR 0210645 A BR0210645 A BR 0210645A
Authority
BR
Brazil
Prior art keywords
alkyl
compound
nhc
heteroaryl
cycloalkyl
Prior art date
Application number
BR0210645-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Nicole Corine Renee Straten
Rudolf Gijsbertus Van Someren
Jurgen Schulz
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR0210645A publication Critical patent/BR0210645A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
BR0210645-0A 2001-07-02 2002-06-25 Composto derivado de tetraidroquinolina, composição farmacêutica, e, uso do composto. BR0210645A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01202531 2001-07-02
PCT/EP2002/007053 WO2003004028A1 (en) 2001-07-02 2002-06-25 Tetrahydroquinoline derivatives

Publications (1)

Publication Number Publication Date
BR0210645A true BR0210645A (pt) 2004-10-05

Family

ID=8180574

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210645-0A BR0210645A (pt) 2001-07-02 2002-06-25 Composto derivado de tetraidroquinolina, composição farmacêutica, e, uso do composto.

Country Status (31)

Country Link
US (2) US8058441B2 (https=)
EP (1) EP1406628B1 (https=)
JP (1) JP4523273B2 (https=)
KR (1) KR100908468B1 (https=)
CN (1) CN1261099C (https=)
AR (1) AR034669A1 (https=)
AT (1) ATE319451T1 (https=)
AU (1) AU2002317848B2 (https=)
BR (1) BR0210645A (https=)
CA (1) CA2452606C (https=)
CY (1) CY1106087T1 (https=)
CZ (1) CZ20042A3 (https=)
DE (1) DE60209734T2 (https=)
DK (1) DK1406628T3 (https=)
EC (1) ECSP034932A (https=)
ES (1) ES2260458T3 (https=)
HR (1) HRP20031080A2 (https=)
HU (1) HUP0400390A2 (https=)
IL (1) IL159288A0 (https=)
IS (1) IS2418B (https=)
MX (1) MXPA03011908A (https=)
NO (1) NO325516B1 (https=)
NZ (1) NZ530198A (https=)
PE (1) PE20030273A1 (https=)
PL (1) PL367638A1 (https=)
PT (1) PT1406628E (https=)
RU (1) RU2347570C2 (https=)
SA (1) SA02230260B1 (https=)
SK (1) SK286759B6 (https=)
WO (1) WO2003004028A1 (https=)
ZA (1) ZA200309921B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20042A3 (en) * 2001-07-02 2004-04-14 Akzo Nobel N. V. Tetrahydroquinoline derivatives
AU2003245773A1 (en) * 2002-02-15 2003-09-04 Glaxo Group Limited Vanilloid receptor modulators
FR2836620B1 (fr) * 2002-02-28 2004-04-16 Snecma Services Instrument de projection thermique
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
TWI322012B (en) * 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
TWI306855B (en) * 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
MXPA05012705A (es) * 2003-05-29 2006-02-08 Astrazeneca Ab Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
KR100554155B1 (ko) * 2003-06-09 2006-02-22 학교법인 포항공과대학교 금속/반도체 나노막대 이종구조를 이용한 전극 구조물 및그 제조 방법
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
US7691848B2 (en) 2005-03-02 2010-04-06 Wyeth Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists
UA92009C2 (ru) 2005-05-04 2010-09-27 Н.В. Органон Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодия
RS51784B (sr) 2005-05-04 2011-12-31 N.V. Organon Derivati dihidropiridina
UA92008C2 (en) * 2005-05-04 2010-09-27 Н.В. Органон 4-PHENYL-5-OXO-l,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY
UA92007C2 (ru) * 2005-05-04 2010-09-27 Н.В. Органон Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодности
EP1879898A2 (en) 2005-05-12 2008-01-23 Wyeth a Corporation of the State of Delaware Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (fsh-r) antagonists
EP1893615A1 (en) 2005-06-09 2008-03-05 Wyeth a Corporation of the State of Delaware Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists
US20070060573A1 (en) * 2005-08-10 2007-03-15 Lars Wortmann Acyltryptophanols
CA2618888A1 (en) * 2005-08-10 2007-02-15 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
EP1932831A1 (en) * 2006-12-13 2008-06-18 Bayer Schering Pharma Aktiengesellschaft 1,2-Diarylacetylene Derivatives of Acyltryptophanols
US20080221195A1 (en) * 2006-12-13 2008-09-11 Lars Wortmann 1,2-diarylacetylene derivatives of acyltryptophanols
TWI410422B (zh) * 2007-01-15 2013-10-01 Mitsubishi Tanabe Pharma Corp 縮合四氫喹啉衍生物及其醫藥用途
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
CA2680761A1 (en) * 2007-03-22 2008-09-25 Astrazeneca Ab Quinoline derivatives for the treatment of inflammatory diseases
TW200918058A (en) * 2007-08-31 2009-05-01 Organon Nv TSH receptor antagonizing tetrahydroquinoline compounds
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
RU2359684C1 (ru) * 2008-01-23 2009-06-27 Закрытое акционерное общество "СКАЙ ЛТД" Способ лечения эндометриоза
TW200944523A (en) 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
US8071587B2 (en) 2009-05-27 2011-12-06 N. V. Organon (Dihydro)imidazoiso[5,1-A]quinolines
TWI461426B (zh) * 2009-05-27 2014-11-21 Merck Sharp & Dohme (二氫)咪唑並異〔5,1-a〕喹啉類
TW201116531A (en) 2009-07-29 2011-05-16 Organon Nv Ring-annulated dihydropyrrolo[2,1-a]isoquinolines
US8431564B2 (en) 2009-07-29 2013-04-30 Merck Sharp & Dohme B.V. Ring-annulated dihydropyrrolo[2,1-α]isoquinolines
TW201116515A (en) 2009-07-31 2011-05-16 Organon Nv Dihydrobenzoindazoles
DK2624695T3 (en) * 2010-10-08 2016-01-04 Nivalis Therapeutics Inc NOVEL SUBSTITUTED quinoline-RELATIONS AS S-NITROSOGLUTATHIONREDUKTASEINHIBITORER
US8546427B2 (en) * 2010-10-20 2013-10-01 Hoffmann-La Roche Inc. Tetrahydroquinoline derivatives
WO2016018553A1 (en) * 2014-07-30 2016-02-04 Henkel IP & Holding GmbH Cure accelerators for anaerobic curable compositions
WO2019089412A1 (en) * 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
CN119954701A (zh) * 2024-06-18 2025-05-09 青岛润农化工有限公司 一种丁醚脲的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2686182A (en) 1950-12-07 1954-08-10 Basf Ag O-hydroxy-dihydro-quinoline carboxylic acids
EP0303306B1 (en) 1987-08-08 1993-03-10 Akzo N.V. Contraceptive implant
EP1043325B1 (en) * 1994-12-22 2004-06-16 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US6235755B1 (en) * 1998-08-07 2001-05-22 Applied Research Systems Ars Holding N.A. FSH mimetics for the treatment of infertility
JP2000143636A (ja) * 1998-09-02 2000-05-26 Sumitomo Pharmaceut Co Ltd アミノ誘導体
US6200963B1 (en) * 1999-03-31 2001-03-13 American Home Products Corporation Aryl sulfonic acids as FSH antagonists
CZ20042A3 (en) 2001-07-02 2004-04-14 Akzo Nobel N. V. Tetrahydroquinoline derivatives
TWI306855B (en) 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives
TWI322012B (en) 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
CA2452606C (en) 2011-09-13
ES2260458T3 (es) 2006-11-01
SK286759B6 (sk) 2009-05-07
SK16342003A3 (sk) 2004-07-07
IL159288A0 (en) 2004-06-01
HUP0400390A2 (hu) 2004-09-28
KR20040030714A (ko) 2004-04-09
KR100908468B1 (ko) 2009-07-21
MXPA03011908A (es) 2004-06-03
RU2347570C2 (ru) 2009-02-27
DE60209734D1 (de) 2006-05-04
CA2452606A1 (en) 2003-01-16
ZA200309921B (en) 2005-03-22
CY1106087T1 (el) 2011-06-08
EP1406628A1 (en) 2004-04-14
NO325516B1 (no) 2008-06-02
IS2418B (is) 2008-10-15
CZ20042A3 (en) 2004-04-14
CN1261099C (zh) 2006-06-28
RU2004102693A (ru) 2005-06-27
JP4523273B2 (ja) 2010-08-11
NO20035763L (no) 2003-12-29
ATE319451T1 (de) 2006-03-15
SA02230260B1 (ar) 2007-03-25
PL367638A1 (en) 2005-03-07
US20120202996A1 (en) 2012-08-09
DE60209734T2 (de) 2006-08-31
US20040236109A1 (en) 2004-11-25
PT1406628E (pt) 2006-06-30
CN1529601A (zh) 2004-09-15
HK1061810A1 (en) 2004-10-08
AU2002317848B2 (en) 2006-08-31
NZ530198A (en) 2005-11-25
HRP20031080A2 (en) 2004-04-30
JP2004535456A (ja) 2004-11-25
ECSP034932A (es) 2004-02-26
US8058441B2 (en) 2011-11-15
US8258293B2 (en) 2012-09-04
PE20030273A1 (es) 2003-03-21
IS7071A (is) 2003-12-11
AR034669A1 (es) 2004-03-03
DK1406628T3 (da) 2006-07-03
WO2003004028A1 (en) 2003-01-16
EP1406628B1 (en) 2006-03-08

Similar Documents

Publication Publication Date Title
BR0210645A (pt) Composto derivado de tetraidroquinolina, composição farmacêutica, e, uso do composto.
BR0213790A (pt) Derivados de aminobenzamida como inibidores de glicogênio sintase cinase 3beta
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
IL154350A (en) Phenylalanine derivatives and pharmaceutical preparations containing them
AUPR213700A0 (en) Antiviral agents
AU5699399A (en) Pyridyl-bridgehead derivatives and their analogues, pharmaceutical compositions and their use as inhibitors of nicotinic cholinergic receptors
EP1340755A4 (en) AGENT WITH EFFECT AGAINST HELICOBACTER
AU4661900A (en) Noscapine derivatives as adjuvant compositions and methods of use thereof
DK1206189T3 (da) Rotavirusvaccineformuleringer
ZA200603538B (en) P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
EP1886691A3 (en) A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug
ATE401056T1 (de) Formoterol und ciclesonid aerosol-formulierungen
BR0307027A (pt) Compostos derivados de nitróxi de compostos esteróides, uso dos compostos, e, formulações farmacêuticas
CO5271717A1 (es) Combinaciones farmaceuticas
WO2002015959A3 (en) Compounds and compositions for delivering active agents
WO2004014389A8 (en) 3,4-dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors
NO20004273D0 (no) Streptograminderivater, deres fremstilling samt preparater inneholdende forbindelsene
AU2001230898A1 (en) Formulations and methods for administration of pharmacologically or biologicallyactive compounds
GEP20063754B (en) Quinoline Derivatives and Use Thereof as Antitumor Agents
ATE371644T1 (de) Neues alkaloidderivat und dieses enthaltende pharmazeutische zusammensetzung
WO2003082867A8 (en) Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents
DK0880520T3 (da) Benzo[c]quinolinderivater, deres fremstilling af anvendelse som 5-alfa-reduktaseinhibitorer
WO2002038563A3 (en) Condensed pyrazindione derivatives as pde inhibitors
SE0302571D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE350064T1 (de) Pharmazeutische zusammensetzungen von rapamycines

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.